BioMedNewsBreaks – Panbela Therapeutics Inc. (NASDAQ: PBLA) Closes on Public Offering Totaling About $8.5M

Panbela Therapeutics (NASDAQ: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, has closed on its previously announced public offering. The offering consisted of 2,270,000 shares of its common stock or prefunded warrants in lieu thereof as well as two classes of warrants to purchase up to 4,540,000 shares of common stock (public warrants). The offerings were at a purchase price of $3.75 per share and associated public warrants and $3.749 per prefunded warrant and associated public warrants. According to the announcement, the prefunded warrants have an exercise price of $0.001 per share. The company reported that gross proceeds from the public offering totaled an estimated $8.5 million before deducting placement agent fees, commissions and offering expenses. The company anticipates using the funds for continued clinical development of its product candidates as well as working capital, business development and other general corporate purposes. Roth Capital Partners acted as sole placement agent of the offering.

To view the full press release, visit https://ibn.fm/nFSLx

About Panbela Therapeutics Inc.

Panbela Therapeutics is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. Panbela’s lead assets are Ivospemin (SBP-101) and Flynpovi. For more information about the company, please visit www.Panbela.com

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork